Astrazeneca Share News (AZN)

Sanofi may win U.S. approval of $3 bln eczema drug by March

Sept 26 (Reuters) - French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March. Sanofi badly needs new products to make up for flag

AstraZeneca pulls cancer drug application in Europe

LONDON, Sept 21 (Reuters) - AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised by regulators reviewing the product. However, the Britis

Monday broker round-up

(ShareCast News) - Lloyds: Jefferies reiterates buy with a target price of 67p. Astrazeneca: UBS reiterates buy, 5480p target. Britvic: JP Morgan keeps at underweight with a 590p target. Unilever: UBS reiterates neutral with a 3380p target. IHG: HSBC starts coverage at reduce with a 2900p target.

Britain's FTSE falls as banking stocks lose ground

(ADVISORY - Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 ends down 0.3 pct at 6,710.28 points * Hefty Deutsche Bank demand hits banks * FTSE 100 still up around 8 pct so far

Astrazeneca says Forxiga combination beats use of drug alone

FRANKFURT, Sept 16 (Reuters) - AstraZeneca said combining its Forxiga type-2 diabetes drug with older medicine Bydureon was more effective at controlling blood sugar levels than treatment with either drug on its own. In a late stage trial, Forxiga and Bydureon were tested on patients whose

UPDATE 2-Aspen Pharmacare moves into China as South Africa sales dip

(Recasts with growth outside home market; adds CEO comment; adds smaller rival) JOHANNESBURG, Sept 14 (Reuters) - South Africa's Aspen Pharmacare Holdings will use its recent acquisitions of GlaxoSmithKline and AstraZeneca product lines to move into China, the firm's chief executive said.</

Broker tips: Pets at Home, Wood Group, Astrazeneca

(ShareCast News) - Citigroup initiated coverage of Pets at Home at 'buy' with a 275p price target, given its expectation of the medium-term margin upside opportunity and cash returns. The bank reckons that over the next 10 years, the vet business could generate an incremental £40m earnings before in

BUZZ-AstraZeneca: top FTSE 100 gainer on lung cancer drug hopes

** AstraZeneca top FTSE 100 gainer, up 0.6% in sharply lower market, after Jefferies calls out multibillion-dollar potential of durvalumab plus tremelimumab combination immunotherapy in lung cancer ** Price target upgraded to £58 a share from £54 ** Broker (4 stars for recommendatio

BUZZ-AstraZeneca: top FTSE 100 gainer on lung cancer drug hopes

** AstraZeneca top FTSE 100 gainer, up 0.6% in sharply lower market, after Jefferies calls out multibillion-dollar potential of durvalumab plus tremelimumab combination immunotherapy in lung cancer ** Price target upgraded to £58 a share from £54 ** Broker (4 stars for recommendatio

Monday broker round-up

(ShareCast News) - Autotrader: Barclays reiterates equal-weight with a target price of 375p. Hikma: Jefferies maintains buy with a 2500p target. Wood Group: Exane BNP Paribas upgrades to buy with a 815p target. Man Group: Citigroup upgrades to buy with a 137p target. McCarthy & Stone: Goldman Sac

Jefferies upgrades AstraZeneca to 'buy'

(ShareCast News) - Jefferies upgraded AstraZeneca to 'buy' from 'hold' and lifted the price target to 5,800p from 5,400p saying it sees a much higher probability of success and larger market opportunity from the MYSTIC study than consensus implies. The MYSTIC study is a global, phase 3 study of the

AstraZeneca Starts Two Trials On Type-2 Diabetes Drug

Consort Medical signs agreement with AstraZeneca

(ShareCast News) - Consort medical, a provider of advanced technology for drugs, has signed a new contract with pharmaceutical giant AstraZeneca for the supply of its Bespak respiratory devices. AstraZeneca and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Be

Consort Medical Sees Little Brexit Impact; Signs Deal With AstraZeneca

GSK's triple drug cuts flare-ups in chronic lung disease

By Ben Hirschler LONDON, Sept 6 (Reuters) - An experimental three-in-one inhaled drug from GlaxoSmithKline significantly cut flare-ups in patients with chronic lung disease in a clinical trial, researchers said on Tuesday. GSK is ahead of rivals AstraZeneca and Novartis in developing